Hormonal
High-dose GLP-1 receptor agonists (specifically semaglutide 2.4 mg) combined with lifestyle interventions produce significant, sustainable weight loss (-14.9% body weight) and improved glycemic control in patients with diabesity, making them superior to insulin and other antidiabetic agents regarding weight management.
If you have both diabetes and obesity, ask your doctor about GLP-1 agonists like semaglutide (2.4 mg). This treatment, combined with diet and exercise changes, has been shown to help patients lose nearly 15% of their body weight over 68 weeks while also controlling blood sugar. It is often more effective for weight loss than insulin, which tends to cause weight gain. Be aware that you might experience some nausea or vomiting at first, but these symptoms usually go away, and the long-term health benefits are significant.
A recent study (Wilding et al[81]) showed that the use of 2.4 mg semaglutide alongside lifestyle intervention, resulted in sustainable weight loss after 68 wk (-14.9% for semaglutide vs -2.4% for placebo)... Therefore, GLP-1 agonists should be the first-line injectable therapy for consideration in diabesity patients, with remarkable benefits on body weight while also resulting in improved glycaemic control.
Why this rating
Based on a cited landmark RCT (Wilding et al.) showing large effect sizes, though the paper itself is a narrative review.
Source
Management of diabesity: Current concepts
Maria Michaelidou et al. · World Journal of Diabetes · 2023
DOI 10.4239/wjd.v14.i4.396
More from this paper
- SGLT-2 inhibitors reduce body weight (0.9-2.5 kg) and improve cardiovascular and renal outcomes in patients with diabesity by inducing glycosuria, making them a valuable class of medication for managing both metabolic and organ-specific risks.Good
- Weight loss of 15 kg can induce remission of Type 2 Diabetes in approximately 70% of individuals, and even smaller weight losses (5 kg) improve insulin sensitivity and glycemic control, highlighting the primacy of lifestyle interventions in diabesity management.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →